GlassScriptPhysician profile
Brian Yung
NPI 1902070618
$2,024.34
in general payments reported to CMS, 2019-2025
23 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.20 · 2022: $271 · 2023: $621 · 2024: $618 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,011.80 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $190.20 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $127.16 | 2022-2024 | Mounjaro, Jardiance |
| Corcept Therapeutics | $104.90 | 2022-2023 | Korlym |
| Pfizer INC. | $70.00 | 2023-2024 | |
| Abbvie INC. | $59.21 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $51.89 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.88 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.02 | 2023-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $43.21 | 2022 | |
| Abbott Laboratories | $36.40 | 2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2022-2023 | Eliquis |
| Amgen INC. | $29.06 | 2022-2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $28.78 | 2024-2025 | Farxiga |
| Amarin Pharma, INC. | $28.47 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.91 | 2025 | Veozah |
| Lundbeck LLC | $18.73 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $17.18 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $17.11 | 2022 | |
| Esperion Therapeutics, INC. | $15.43 | 2024 | Nexletol |
| Currax Pharmaceuticals LLC | $13.63 | 2025 | Contrave |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.54 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Yung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.